Lorlatinib is a TKI with activity in ROS1 fusion NSCLC, and preliminary results from an ongoing phase 2 study indicate intracranial responses in 3 of 12 patients with brain metastases (42). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.